Advertisement

Topics

Samsung, Biogen version of AbbVie's Humira approved in Europe

22:10 EDT 24 Aug 2017 | Reuters

(Reuters) - Biogen Inc's version of AbbVie Inc's blockbuster arthritis drug Humira has been approved by European Union regulators, Biogen and joint venture partner Samsung Biologics said on Thursday.

Original Article: Samsung, Biogen version of AbbVie's Humira approved in Europe

NEXT ARTICLE

More From BioPortfolio on "Samsung, Biogen version of AbbVie's Humira approved in Europe"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gout
According to the National Arthritis Data Workgroup, an estimated 6 million people in the United States report having experienced gout at some point in their lives. In fact, gout is the most common form of inflammatory arthritis in men over the age of 40....

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...